Fibroblast growth factor 21 (FGF21) therapy attenuates left ventricular dysfunction and metabolic disturbance by improving FGF21 sensitivity, cardiac mitochondrial redox homoeostasis and structural changes in pre-diabetic rats

• Main Authors: P. Tanajak, P. Sa-Nguanmoo, X. Wang, G. Liang, X. Li, C. Jiang, S. C. Chattipakorn, N. Chattipakorn
• Format: Journal
• Published: 2018
• Subjects: Biochemistry, Genetics and Molecular Biology
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84979021421&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/55169
• Institution: Chiang Mai University

© 2016 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd Fibroblast growth factor 21 (FGF21) acts as a metabolic regulator and exerts cardioprotective effects. However, the effects of long-term FGF21 administration on the heart under the FGF21-resistant condition in obese,...